Gamelin Erick
SEC CIK 1950551 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | Chief Medical Off | 52.6K | — | $804.00 | 14 | 2022-11-14 | 2026-08-18 |
Most active insiders at ACRV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Blume-Jensen Peter | Pres, CEO, Dir | $82.3K | $34.4K |
| 2 | Devroe Eric | COO | $17.2K | $1,214 |
| 3 | Levy Adam D. | CFO | $15.0K | $1,793 |
| 4 | Miller Mary | CLO | — | $1,380 |
| 5 | Gamelin Erick | Chief Development Off | — | $804.00 |
| 6 | Peterson Katharine | CAO | — | $203.01 |
| 7 | Levin Michaela | Chief Business Off | — | — |
| 8 | Palani Santhosh | Dir | — | — |
| 9 | Masson Kristina | EVP - Business Ops, Dir | — | — |
| 10 | DiRocco Derek | Dir | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 16:08 | 2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | S - Sale | $2.01 | -400 | 52.6K | -0.8% | -$804.00 | |
| 2026-05-20 16:29 | 2026-05-18 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | A - Grant | $0.00 | +38.6K | 53.0K | +268% | $0 | |
| 2026-05-18 16:11 | 2026-05-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $1.92 | -404 | 14.4K | -3% | -$775.68 | |
| 2026-02-18 | 2026-02-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $1.63 | -471 | 14.8K | -3% | -$767.73 | |
| 2025-11-18 | 2025-11-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $2.24 | -403 | 15.3K | -3% | -$902.72 | |
| 2025-08-18 | 2025-08-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $1.39 | -403 | 15.7K | -3% | -$560.17 | |
| 2025-05-16 | 2025-05-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $1.14 | -403 | 16.1K | -2% | -$459.42 | |
| 2025-02-19 | 2025-02-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $5.42 | -469 | 16.5K | -3% | -$2,542 | |
| 2024-11-18 | 2024-11-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $7.92 | -402 | 17.0K | -2% | -$3,184 | |
| 2024-08-16 | 2024-08-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $7.02 | -402 | 17.4K | -2% | -$2,822 | |
| 2024-05-16 | 2024-05-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $8.36 | -402 | 17.8K | -2% | -$3,361 | |
| 2024-02-16 | 2024-02-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Off | F - Tax | $3.40 | -468 | 18.2K | -3% | -$1,591 | |
| 2023-11-16 | 2023-11-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Medical Off | F - Tax | $5.08 | -1,395 | 18.6K | -7% | -$7,087 | |
| D | 2022-11-16 | 2022-11-14 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Medical Off | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations